Tanvex BioPharma Inc Cash Flow Conversion Efficiency

Latest as of March 2026: -0.058x

Tanvex BioPharma Inc cash flow conversion efficiency. Based on the latest financial reports, Tanvex BioPharma Inc (6541) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-309.37 Million ≈ $-9.75 Million USD) by net assets (NT$5.36 Billion ≈ $169.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Tanvex BioPharma Inc (2013–2025)

Cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2025. This chart illustrates how Tanvex BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Tanvex BioPharma Inc for real-time trading data and today's change.

Tanvex BioPharma Inc Cash Flow Conversion Ratio Explained

Tanvex BioPharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Tanvex BioPharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tanvex BioPharma Inc ranked by their cash flow conversion efficiency. Also see 6541 market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
centrotherm international AG F:CTNK	0.077x
Asia Cuanon Tech (Shanghai) SHG:603378	-0.615x
Dongsung FineTec Co. Ltd KQ:033500	-0.011x
Treace Medical Concepts Inc NASDAQ:TMCI	0.094x
Spok Holdings Inc NASDAQ:SPOK	0.017x
Senao International Co Ltd TW:2450	-0.047x
RF Capital Group Inc TO:RCG	0.017x
AstroNova Inc NASDAQ:ALOT	0.039x

Annual Cash Flow Conversion Efficiency for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tanvex BioPharma Inc from 2013 to 2025. Review financial agility of Tanvex BioPharma Inc to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$5.69 Billion ≈ $179.39 Million	NT$-1.01 Billion ≈ $-31.68 Million	-0.177x	+86.29%
2024-12-31	NT$893.31 Million ≈ $28.14 Million	NT$-1.15 Billion ≈ $-36.25 Million	-1.288x	+26.24%
2023-12-31	NT$821.11 Million ≈ $25.87 Million	NT$-1.43 Billion ≈ $-45.17 Million	-1.746x	-82.16%
2022-12-31	NT$1.39 Billion ≈ $43.84 Million	NT$-1.33 Billion ≈ $-42.02 Million	-0.959x	-93.15%
2021-12-31	NT$2.79 Billion ≈ $88.05 Million	NT$-1.39 Billion ≈ $-43.70 Million	-0.496x	+27.24%
2020-12-31	NT$2.62 Billion ≈ $82.57 Million	NT$-1.79 Billion ≈ $-56.32 Million	-0.682x	-8.89%
2019-12-31	NT$3.03 Billion ≈ $95.49 Million	NT$-1.90 Billion ≈ $-59.82 Million	-0.626x	-64.42%
2018-12-31	NT$4.21 Billion ≈ $132.79 Million	NT$-1.61 Billion ≈ $-50.59 Million	-0.381x	-17.86%
2017-12-31	NT$3.75 Billion ≈ $118.12 Million	NT$-1.21 Billion ≈ $-38.19 Million	-0.323x	-38.59%
2016-12-31	NT$3.57 Billion ≈ $112.57 Million	NT$-833.43 Million ≈ $-26.26 Million	-0.233x	+50.64%
2015-12-31	NT$1.45 Billion ≈ $45.62 Million	NT$-684.20 Million ≈ $-21.56 Million	-0.473x	+35.83%
2014-12-31	NT$589.64 Million ≈ $18.58 Million	NT$-434.17 Million ≈ $-13.68 Million	-0.736x	-23.91%
2013-12-31	NT$403.64 Million ≈ $12.72 Million	NT$-239.86 Million ≈ $-7.56 Million	-0.594x	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$227.50 Million

NT$7.22 Billion TWD

Market Cap Rank

#15843 Global

#721 in Taiwan

Share Price

NT$27.25

Change (1 day)

-2.50%

52-Week Range

NT$27.25 - NT$63.30

All Time High

NT$287.73